TWI454221B - Composition and method for inhibiting formation of body fat - Google Patents

Composition and method for inhibiting formation of body fat

Info

Publication number
TWI454221B
TWI454221B TW097126609A TW97126609A TWI454221B TW I454221 B TWI454221 B TW I454221B TW 097126609 A TW097126609 A TW 097126609A TW 97126609 A TW97126609 A TW 97126609A TW I454221 B TWI454221 B TW I454221B
Authority
TW
Taiwan
Prior art keywords
composition
body fat
inhibiting formation
inhibiting
formation
Prior art date
Application number
TW097126609A
Other languages
English (en)
Other versions
TW201002212A (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to TW097126609A priority Critical patent/TWI454221B/zh
Priority to US12/457,861 priority patent/US20100009014A1/en
Priority to AU2009202723A priority patent/AU2009202723B2/en
Priority to CA2670964A priority patent/CA2670964C/en
Priority to RU2009125692/15A priority patent/RU2446819C2/ru
Priority to KR1020090062187A priority patent/KR101121874B1/ko
Priority to MX2009007546A priority patent/MX2009007546A/es
Priority to JP2009165198A priority patent/JP4972673B2/ja
Publication of TW201002212A publication Critical patent/TW201002212A/zh
Application granted granted Critical
Publication of TWI454221B publication Critical patent/TWI454221B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/02—Making cheese curd
    • A23C19/05—Treating milk before coagulation; Separating whey from curd
    • A23C19/053—Enrichment of milk with whey, whey components, substances recovered from separated whey, isolated or concentrated proteins from milk
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/02—Making cheese curd
    • A23C19/05—Treating milk before coagulation; Separating whey from curd
    • A23C19/054—Treating milk before coagulation; Separating whey from curd using additives other than acidifying agents, NaCl, CaCl2, dairy products, proteins, fats, enzymes or microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1322—Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/15—Reconstituted or recombined milk products containing neither non-milk fat nor non-milk proteins
    • A23C9/1512—Reconstituted or recombined milk products containing neither non-milk fat nor non-milk proteins containing isolated milk or whey proteins, caseinates or cheese; Enrichment of milk products with milk proteins in isolated or concentrated form, e.g. ultrafiltration retentate
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1522—Inorganic additives, e.g. minerals, trace elements; Chlorination or fluoridation of milk; Organic salts or complexes of metals other than natrium or kalium; Calcium enrichment of milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW097126609A 2008-07-14 2008-07-14 Composition and method for inhibiting formation of body fat TWI454221B (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
TW097126609A TWI454221B (en) 2008-07-14 2008-07-14 Composition and method for inhibiting formation of body fat
US12/457,861 US20100009014A1 (en) 2008-07-14 2009-06-24 Use of composition for manufacture of medicant and method for inhibiting formation of body fat
AU2009202723A AU2009202723B2 (en) 2008-07-14 2009-06-30 Use of composition for manufacture of medicant and method for inhibiting formation of body fat
CA2670964A CA2670964C (en) 2008-07-14 2009-07-06 Use of composition for manufacture of medicant and method for inhibiting formation of body fat
RU2009125692/15A RU2446819C2 (ru) 2008-07-14 2009-07-07 Применение композиции для ингибирования образования жира тела и способ ингибирования образования жира тела
KR1020090062187A KR101121874B1 (ko) 2008-07-14 2009-07-08 의약의 제조를 위한 조성물의 용도와 체지방 형성을 억제하는 방법
MX2009007546A MX2009007546A (es) 2008-07-14 2009-07-13 Uso de una composicion para la elaboracion de un medicamento y metodo para inhibir la formacion de grasa corporal.
JP2009165198A JP4972673B2 (ja) 2008-07-14 2009-07-14 体脂肪の形成を抑制するための薬剤組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW097126609A TWI454221B (en) 2008-07-14 2008-07-14 Composition and method for inhibiting formation of body fat

Publications (2)

Publication Number Publication Date
TW201002212A TW201002212A (en) 2010-01-16
TWI454221B true TWI454221B (en) 2014-10-01

Family

ID=41505375

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097126609A TWI454221B (en) 2008-07-14 2008-07-14 Composition and method for inhibiting formation of body fat

Country Status (8)

Country Link
US (1) US20100009014A1 (zh)
JP (1) JP4972673B2 (zh)
KR (1) KR101121874B1 (zh)
AU (1) AU2009202723B2 (zh)
CA (1) CA2670964C (zh)
MX (1) MX2009007546A (zh)
RU (1) RU2446819C2 (zh)
TW (1) TWI454221B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI788561B (zh) * 2019-05-08 2023-01-01 加特福生物科技股份有限公司 促進脂質代謝或幫助體重控制的組成物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9657845B2 (en) * 2014-10-07 2017-05-23 Asm Ip Holding B.V. Variable conductance gas distribution apparatus and method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200701987A (en) * 2005-07-05 2007-01-16 Maxluck Biotechnology Corp Composition and method for controlling and preventing heart disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194615A (en) * 1983-07-08 1993-03-16 The William Seroy Group Synthetic GTF chromium nicotinate material and its preparation
JPH0623102B2 (ja) * 1985-08-22 1994-03-30 日本臓器製薬株式会社 脂質低下剤
US5480657A (en) * 1993-10-27 1996-01-02 Allen; Ann De Wees T. Composition comprising caffeine chromium and fructose for weight control and use thereof
US5948772A (en) 1998-08-28 1999-09-07 Ambi Inc. Chromium picolinate compositions and uses thereof
CN1114618C (zh) * 2000-05-19 2003-07-16 程伶辉 三价铬复合物、其乳制品及其制造方法
JP3633852B2 (ja) 2000-06-06 2005-03-30 伶輝 程 三価クロム複合物、その乳製品およびその製造方法
DE60104450T2 (de) * 2000-09-21 2005-09-15 Nutrition 21, Inc. Chrom enthaltende zusammensetzung zur behandlung von diabetes, zur verbesserung der insulinsensitivität und zur reduktion von hyperglykämie, hypercholesterolämie und des körperfettanteils
EP1466621A4 (en) * 2001-12-28 2009-05-27 Nrl Pharma Inc COMPOSITIONS FOR ENHANCING LIPID METABOLISM
US20050214384A1 (en) * 2002-04-23 2005-09-29 Vijaya Juturu Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
US7744930B2 (en) * 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
TW200605902A (en) * 2004-08-05 2006-02-16 Maxluck Biotechnology Corp Composition for lowering blood lipid
CN101141888A (zh) * 2004-12-14 2008-03-12 聪明燃烧制剂有限公司 促进减肥的辅助性膳食组合物
JP2009525990A (ja) * 2006-02-09 2009-07-16 ナショナル・リサーチ・カウンシル・オブ・カナダ 医薬組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200701987A (en) * 2005-07-05 2007-01-16 Maxluck Biotechnology Corp Composition and method for controlling and preventing heart disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kaats, G. R. et al. A randomized, double-masked, placebo-controlled study of the effects of chromium picolinate supplementation on body composition: A replication and extension of a previous study. Current Therapeutic Research. 1998. 59(6), 379-388. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI788561B (zh) * 2019-05-08 2023-01-01 加特福生物科技股份有限公司 促進脂質代謝或幫助體重控制的組成物

Also Published As

Publication number Publication date
US20100009014A1 (en) 2010-01-14
TW201002212A (en) 2010-01-16
CA2670964C (en) 2014-09-30
AU2009202723A1 (en) 2010-01-28
JP2010018615A (ja) 2010-01-28
RU2009125692A (ru) 2011-01-20
KR20100007752A (ko) 2010-01-22
JP4972673B2 (ja) 2012-07-11
KR101121874B1 (ko) 2012-03-19
MX2009007546A (es) 2010-03-23
AU2009202723B2 (en) 2013-10-31
RU2446819C2 (ru) 2012-04-10
CA2670964A1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
ZA201107789B (en) Antimicrobial composition and related method of use
EP2294156A4 (en) METHOD FOR PREVENTING AND REDUCING SCALE FORMATION
EP2396019A4 (en) METHOD AND COMPOSITIONS FOR SKIN TREATMENT
EP2249914A4 (en) IMPLANT EQUIPPED FOR NERVE LOCATION AND METHOD OF USE
HK1150839A1 (zh) 用於治療性抗體的組合物及方法
EP2361089A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE
ZA201006988B (en) Method and compositions for treatment of cancer
HK1158522A1 (en) Composition and method for treatment of mrsa
PL2376077T3 (pl) Kompozycja i sposób leczenia cukrzycy
EP2291474A4 (en) DECORATIVE COMPOSITION AND USE THEREOF
EP2350641A4 (en) Methods of Treatment
GB0812890D0 (en) Compositions and methods of making compositions
HK1167101A1 (zh) 用於治療多發性硬化症的組合物及方法
HK1164958A1 (zh) 表面組合物及應用方法
EP2480246A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF DIABETES
ZA201102207B (en) Cinnamandehyde-allicin compositions and their method of use
EP2285398A4 (en) METHOD AND COMPOSITIONS FOR TREATING ADIPOSITAS
EP2473635A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROPATHIC PAIN
TWI454221B (en) Composition and method for inhibiting formation of body fat
EP2411020A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMORRHAGE
EP2470016A4 (en) SYNERGISTIC COMPOSITION AND METHOD OF USE
GB0817579D0 (en) Method and composition for the removal of tattoos
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia
GB0820804D0 (en) Perinropril composition and method of use thereof
PL385436A1 (pl) Sposób otrzymywania 5-hydroksykreatyniny i N-metyloguanidyny